MolPort-001-783-655

USFDA’s list of drugs that need generic alternatives

In its continuous endeavor to bolster the competitiveness of the generics market, the US Food

Mylan board survives shareholder meet; Evaluate lowers drug sales growth forecast

This week, Phispers brings you news on the oversubscription of EU’s online pharmacy Zur Rose,

PharmaCompass finds 500 drugs with ‘no patents and no competition’ in the FDA Orange Book

In April last year, PharmaCompass had shared a list of over 300 different dosage forms of drugs whic

Trump’s comments on drug prices sink pharma stocks; Teva lowers guidance by $ 1 billion

The New Year began with the JP Morgan Healthcare Conference— the drug industry’s annual

Price gouging by Aspen in Italy; explosion at BASF; India acts on illegal Metformin exports

This week, Phispers gets you news on illegal exports of Metformin in India, Hillary Clinton’s

Drugs with no patents and no competition – here’s our list of new ‘price-gouging’ targets

Drug price increases have emerged as a core strategy for generic pharmaceutical companies in the rec